A Phase IIb Randomized Study to Evaluate the Efficacy of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer.

Trial Profile

A Phase IIb Randomized Study to Evaluate the Efficacy of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Capecitabine (Primary) ; Erlotinib; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms GECA
  • Most Recent Events

    • 17 Feb 2017 Primary endpoint (Progression free survival) has not been met.
    • 17 Feb 2017 Results published in the European Journal of Cancer
    • 17 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top